Lycera Corp. recently announced the initiation of its LYC-30937-EC (Enteric Coated) Phase 2 clinical trial for the treatment of patients who are suffering from ulcerative colitis (UC).
The enrollment for the Ulcerative Colitis Phase 2 Study To Assess Remission by Treatment with LYC 30937-EC (UPSTART) study is expected to be up to 120 patients and will evaluate the safety and efficiency of LYC-30937-EC administered to patients with active ulcerative colitis once-a-day orally.
"The initiation of the Phase 2 clinical trial of LYC-30937-EC is an important milestone in Lycera's continued progress and is one of several clinical studies we plan to initiate in the second half of 2016 as we build our portfolio of novel immune modulatory treatments," Lycera President and CEO Paul Sekhri said. "Based upon the results of our preclinical and Phase 1 studies, we believe LYC-30937-EC may possess key advantages for patients, including localized therapy at the site of disease, and the potential for reduced systemic exposure and side effects. Our candidate also offers the convenience of once-daily oral dosing. Despite progress in treatment options for patients with UC, we believe there is still significant need, one where LYC-30937-EC may play an important future role."